Clinical trials: Relapsed or Refractory Neuroblastoma
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer that has recurred following bone marrow or peripheral stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003887
- Testing
- peripheral blood lymphocyte therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Disseminated Neuroblastoma, Recurrent Neuroblastoma
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment.
- Trial name
- NCT00436852
- Testing
- ABT-751, quality-of-life assessment
- Where
- 12 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
This study will combine an oral drug called DFMO with celecoxib (also oral) and two IV chemotherapy medicines called cyclophosphamide and topotecan.
- Trial name
- DFMO (NCT02030964)
- Testing
- DFMO, Celecoxib, Cyclophosphamide
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period…
- Conditions
- Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT07437963
- Testing
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.
- Trial name
- NCT02748135
- Testing
- TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg
- Where
- 10 sites in United States
- Volunteers
- 18 people
- Sponsor
- Oncurious NV
Neuroblastoma
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for early relapsed neuroblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration.
- Trial name
- NCT01505608
- Testing
- TPI 287, Temozolomide, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 14 people
- Sponsor
- Giselle Sholler
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Neuroblastoma
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat.
- Trial name
- NCT07261241
- Testing
- Radiation: 131I-MIBG, Dinutuximab, Vorinostat
- Where
- 13 sites in United States
- Volunteers
- 118 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma
- Trial name
- NCT03213704
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 124 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Refractory and/or Relapsed Metastatic Solid Tumors
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk…
- Trial name
- NCT01804634
- Testing
- Cyclophosphamide, Fludarabine, low dose total body irradiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroblastoma, Rhabdomyosarcoma
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor activity of enoblituzumab administered IV on a…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma
- Trial name
- NCT02982941
- Testing
- Enoblituzumab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- MacroGenics
Neuroblastoma
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells.
- Trial name
- NCT00002748
- Testing
- gene-modified tumor cell vaccine therapy, interleukin-2 gene
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- St. Jude Children's Research Hospital
Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
This phase I trial studies the side effects and the best dose of crizotinib when given together with combination chemotherapy in treating younger patients with solid tumors or anaplastic large cell lymphoma that has returned or…
- Conditions
- Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
- Trial name
- NCT01606878
- Testing
- Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride
- Where
- 23 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Children's Oncology Group
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT03213652
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma, Central Nervous System Embryonal Tumor
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells targeting the oncofetal protein Glypican-2 (GPC2) in pediatric and young…
- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma
- Trial name
- NCT07087002
- Testing
- GPC2-CAR T cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Relapsed Neuroblastoma, Refractory Neuroblastoma
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFβi NK Cell in combination with irinotecan, temozolomide, and dinituximab.
- Trial name
- STING (NCT04211675)
- Testing
- Natural Killer Cells, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Nationwide Children's Hospital